

In Vitro: Natural Compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) Against Sars-Cov2 Strain Isolated from Egypt

Mohamed G. Seadawy^{1*}, Ahmed F. Gad¹, Mohamed Shamel¹, Bassem Elharty¹, Mostfa F. Mohamed¹, Sherine Helmy², Abdo A. Elfiky³, Aya Ahmed⁴, Abdel Rahman N. Zekri⁴

¹Chemistry Department, Main chemical laboratories, Egypt Army, Egypt

²PHARCO Pharmaceuticals, Alexandria, Egypt

³Biophysics Department, Cairo University, Giza, Egypt

⁴Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt

*Corresponding author: Mohamed GS, Chemistry Department, Main chemical laboratories, Egypt Army, Egypt, Mobile: +201000948658; E-mail: biologist202054@yahoo.com

Received: 24-02-2021; Accepted: 10-03-2021; Published: 17-03-2021

Citation: Mohamed GS, Ahmed FG, Mohamed S, Bassem E, Mostfa FM, Sherine H, et al. (2021) *In Vitro*: Natural Compounds (Thymol, Carvacrol, Hesperidine, And Thymoquinone) Against Sars-Cov2 Strain Isolated From Egypt. Clin Immunol Infect Dis Vol 5:2.

Abstract

Background: The current pandemic of the coronavirus disease-2019 (COVID-19) has badly affected our life during the year 2020. SARS-CoV-2 is the primary causative agent of the newly emerged pandemic. Natural flavonoids, Terpenoid and Thymoquinone are tested against different viral and host-cell protein targets. These natural compounds have a good history in treating Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV).

Methods: Molecular docking combined with cytotoxicity and plaque reduction assay is used to test the natural compounds against different viral (Spike, RdRp, and Mpro) and host-cell (TMPRSS II, keap 1, and ACE2) targets.

Results: The results demonstrate the binding possibility of the natural compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) to the viral main protease (Mpro). Some of these natural compounds were approved to start clinical trail from Egypt Center for Research and Regenerative Medicine ECRRM IRB (Certificate No. IRB00012517)

Conclusion: Development of an effective anti-viral for SARS-CoV-2 could help to limit the viral load. Benchmarking testing of those natural compounds against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action would thus be important as soon as practicable.

Keywords: COVID-19; SARS-CoV-2; Natural products; Antivirals; Docking; Plaque reduction assay

Abbreviations

Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Spike Protein (S Protein); Receptor binding domain (RBD); RNA dependent RNA polymerase (RdRp); Inhibition concentration (IC50); Nigella sativa (NS); Thymoquinone (TQ); Hepatitis C virus: (HCV); Angiotensin Converting Enzyme 2 (ACE2); Human Immunodeficiency Virus: (HIV); Transmembrane Protease, Serine (TMPRSS)

Background

By the end of 2019, an outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan city in China was detected and spread all over the world [1]. On 10th October 2020, the number of confirmed cases of coronavirus disease (COVID-19) reached more than 37 M worldwide with +1 M total death, as reported in the World Health Organization (WHO). The associated pneumonia with the novel viral infection, COVID-19, is divided into three phases that correspond to different clinical stages of the disease [2]. Stage 1 is the asymptomatic stage, where the inhaled virus binds to nasal epithelial cells in the nasal cavity and starts replicating. Stage 2 is the upper airway stage, where the virus propagates, migrates down the respiratory tract along the conducting airways, and a more robust innate immune response is triggered. About 20% of the infected patients will progress to stage 3 diseases and develop pulmonary infiltrates. Some of these patients will develop a very severe disease as the virus reaches alveoli in the lung and infects alveolar type II cells in peripheral and sub-pleural areas of the lung [3]. SARS-CoV-2 propagates within type II cells, large numbers of viral particles are released, and the cells undergo apoptosis and die. Therefore, the spectrum of symptomatic

COVID-19 ranges from mild respiratory tract infection to severe pneumonia that may progress to fatal respiratory syndrome and multi-organ malfunctions [2].

Thymol, known as 2-isopropyl-5-methylphenol, is a natural mono-terpenoid phenol derivative of Cymene. It is found in thyme oil and extracted from *Thymus vulgaris* [4]. Thymol is a white crystalline substance that has a pleasant aromatic odor. Thymol also provides the distinctive and robust flavor of the culinary herb thyme.

Carvacrol is known as monoterpenoid phenol and extracted from *Oregano*. It has a characteristic pungent and warm odor [5].

Hesperidine is a common flavone glycoside found in citrus fruit such as lemons and sweet oranges [6,7]. It has several pharmacological activities such as antihyperlipidemic, anti-atherogenic, venotonic, antidiabetic, cardioprotective, anti-hypertensive, and inflammatory actions [6,7]. The anti-inflammatory activity of hesperidin was mainly attributed to its antioxidant defense mechanism and suppression of pro-inflammatory cytokine production [6]. Hesperidin exhibited antiviral activity against the influenza virus through a significant reduction of viral replication.

Nigella sativa (NS) contains many active molecules, such as Thymoquinone (TQ), two forms of alkaloids: isoquinoline alkaloid that includes nigellimine, nigellimine n-oxide and pyrazol alkaloid that includes nigellidine and nigelline [8,9]. TQ is the most abundant constituent in the volatile oil of *Nigella sativa* seeds, and most of the herb's properties are attributed to it [10,11]. It has been reported that NS oil can decrease the viral count of HCV in patients received capsules of NS oil (450 mg) three times a day over a 3-month period [12]. Moreover, two clinical studies documented to sustained sero-reversion of the HIV virus over treatment period of 6 to 12 months [13-15].

Molecular docking represents a promising *in silico* method used to predict the binding affinities of small molecules to proteins as a first step in structure based drug design [16-21]. This study investigated many active ingredients that showed antiviral activities against SARS-CoV-2, such as Thymol, Carvacrol, Hesperidine, and Thymoquinone. Molecular docking is used to test the binding affinities of these natural product derived compounds against different viral and host cell proteins. Additionally cytotoxicity assay and plaque reduction assay are used to verify their antiviral activity against SARS-CoV-2 collected from Egyptian patients.

Materials and Methods

In silico testing

Before performing the docking studies, the tested compounds are retrieved from the PubChem database and then prepared using PyMOL software [22,23]. The structures of the proteins are downloaded from the protein data bank [24]. Autodock Tools are used to prepare the docking input files after adding charges [25]. The docking experiments are performed utilizing Autodock Vina software in triplicates to have a clear depiction of the mode

of action of compounds against their protein targets [26]. SARS-CoV-2 Spike protein (S), The RNA dependent RNA polymerase (RdRp), the main protease (Mpro) are used as protein targets due to its critical role in maintaining the viral infection [27-31]. Additionally, the host-cell receptors, Transmembrane protease, serine 2 (TMPRSS II), Kelch-like ECH-associated protein 1 (KEAP 1) and the Angiotensin Converting Enzyme 2 (ACE2) are targeted due to its fundamental in viral recognition and maintain infectivity for SARS-CoV-2 [32-35]. For each compound, ten interactions were generated and one with best binding affinity was selected. PyMOL software was used to represent and analyze the docking complexes.

Experimental section

All the chemical compounds are purchased from different sources as follow; Thymol purchased from upnature as THYME 100% pure and natural 118 ml, Carvacrol purchased from Zane Hellas as oil of *Oregano* 30 ml, Hesperidin purchased from science-based nutrition as hesperidin methyl chalcone 500 mg -60 veggie caps, and Thymoquinone purchased from prime natural black seed USDA organic 240 ml.

Cytotoxicity assay: Samples were diluted with Dulbecco's Modified Eagle's Medium (DMEM). Stock solutions of the test compounds were prepared in 10% DMSO in ddH₂O. The cytotoxic activity of the extracts were tested in Vero E6 cells by using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method [36] with minor modification. Briefly, the cells were seeded in 96 well-plates (100 µl/well at a density of 3×10⁵ cells/ml) and incubated for 24 hrs at 37°C in 5%CO₂. After 24 hrs, cells were treated with various concentrations of the tested compounds in triplicates. After further 24 hrs, the supernatant was discarded and cell monolayers were washed with sterile phosphate buffer saline (PBS) 3 times and MTT solution (20 µl of 5 mg/ml stock solution) was added to each well and incubated at 37°C for 4 hrs followed by medium aspiration. In each well, the formed formazan crystals were dissolved with 200 µl of acidified isopropanol (0.04 M HCl in absolute isopropanol=0.073 ml HCl in 50 ml isopropanol). Absorbance of formazan solutions were measured at λ_{max} 540 nm with 620 nm as a reference wavelength using a multi-well plate reader. The percentage of cytotoxicity compared to the untreated cells was determined with the following equation.

$$\% \text{ cytotoxicity} = \frac{(\text{absorbance of cells without treatment} - \text{absorbance of cells with treatment}) \times 100}{\text{absorbance of cells without treatment}}$$

The plot of % cytotoxicity versus sample concentration was used to calculate the concentration which exhibited 50% cytotoxicity (IC₅₀).

Plaque reduction assay: Assay was carried out according to the method of [37] in a six well plate where Vero E6 cells (10⁵ cells/ml) were cultivated for 24 hrs at 37°C. Sever Acute Respiratory Syndrome Coronavirus (SARS-CoV2) virus was diluted to give 103 PFU/well and mixed with the safe concentration of the tested compounds and incubated for 1 hour at 37°C before being added to the cells. Growth medium was removed from the cell culture plates and the cells were inoculated with (100 µl/well)

virus with the tested compounds, After 1 hour contact time for virus adsorption, 3 ml of DMEM supplemented with 2% agarose and the tested compounds was added onto the cell monolayer, plates were left to solidify and incubated at 37°C till formation of viral plaques (3 to 4 days). Formalin (10%) was added for two hours then plates were stained with 0.1% crystal violet in distilled water. Control wells were included where untreated virus was incubated with Vero E6 cells and finally plaques were counted and percentage reduction in plaques formation in comparison to control wells was recorded as following:

$$\% \text{ Inhibition} = \frac{\text{viral count (untreated)} - \text{viral count (treated)}}{\text{viral count (untreated)}} \times 100.$$

-Statistical analysis: Analysis was performed using Graphpad Prism 8.0.2. Data are represented as mean \pm SD and statistical significance was evaluated using one-way ANOVA followed by tukey multiple comparison tests.

Results

Many reports showed that different natural product derived compounds have promising results against inflammation and viral infections including the newly emerged viral infection (SARS-CoV-2) [15,38-40]. Different natural compounds and their derivatives proved its binding affinity against different SARS-CoV-2 and host-cell targets [38,39,41].

Figure 1 shows the 2D structures of the selected natural compounds used in the current study against viral and host-cell protein targets.




Figure 1 The structures of the natural compounds used in the study retrieved from the PubChem database.

Three SARS-CoV-2 proteins are targeted in this study including the viral, host-cell recognizing critical element, spike protein (**Figure 2A**), the vital viral enzyme RNA dependent RNA polymerase (RdRp), responsible for the polymerization of the complement RNA copy, and the Main protease (Mpro) of SARS-CoV-2, which is critical for polyprotein processing (**Figure 2B**) [42-47]. The spike protein trimers over the virions take different conformations during infection such as the prefusion and postfusion. The prefusion has open and closed conformations in which one or two of the receptor binding domains (RBD) are exposed (open) or immersed into the trimer (close) [30,48].




Figure 2 The 3D structures of the SARS-CoV-2 protein targets used in the study. **A**) The structure of SARS-CoV-2 Spike protein (PDB ID: 6VYB) represented by colored cartoons in side (left) and top (right) views. The receptor binding domain (RBD) is circled in both views of the spike. **B**) The structure of the SARS-CoV-2 RdRp (PDB ID: 7BTF) and Mpro (PDB ID: 6Y84) depicted in colored cartoons. The structures are represented using PyMOL software.

Table 1 shows the binding affinity calculated using AutoDock Vina software for the docking of the natural compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) against the SARS-CoV-2 Mpro as a protein target. The standard compound Chloroquine is used to assess the binding affinity of the natural compounds against the Mpro. As reflected from the values, Carvacrol, Hesperidine, and Thymoquinone show comparable binding affinities (-7.0, -6.9, and -6.9 kcal/mol, respectively) to SARS-CoV-2 Mpro compared to that of the standard compound (-7.2 kcal/mol). Thymol show slightly higher (worse) binding

affinity value (-5.8 kcal/mol) compared to Chloroquine but still able to bind the SARS-CoV-2 Mpro tightly. **Figures 3A** and **3B** show the 3D poses for the docking complexes. The four compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) are able to bind to the active site of the Mpro (His41 and Cys145).

Compound	Binding affinity(kcal/mol)
Thymol	-5.8
Carvacrol	-7.0
Hesperidine	-6.9
Thymoquinone	-6.9
Chloroquine(standard)	-7.2

Table 1 The binding affinity (in kcal/mol) of the natural compounds against the main protease of SARS-CoV-2 calculated using AutoDock Vina software.




Figure 3 (A) The docking complexes formed after the docking of Thymol, Carvacrol, Hesperidine, and Thymoquinone into the SARS-CoV-2 Mpro active site. (B) The superposition of all the compounds. The protein is represented with green cartoon, while ligands are in cyan and orange sticks.

The half-maximal inhibitory concentration (IC50) of thymol, carvacrol, hesperidin, and thymoquinone

The effect of different concentrations of the compounds on the cellular proliferation of Vero E6 cell line following 24 h of treatment was determined using MTT assay.

Results of the present work revealed a concentration-dependent cytotoxic effect of Thymol (617 μ M), Carvacrol (464 μ M), Hesperidine (5.58 μ M) and Thymoquinone (3.9 μ M) on Vero E6 cell line as shown in **Figure 4**.




Figure 4 Effect of different concentrations Thymol, Carvacrol, and Thymoquinone on the cellular proliferation of Vero E6 cell line following 24 h of treatment. Values are expressed as the mean \pm SD (n=3). Dose response curves were fitted using GraphPad prism 8.0.2 to determine IC50 values.

Discussion

Our results revealed that Hesperidine was the most affective natural product against SARS-CoV-2 in Egyptians patients, as it caused inhibition to approximately 100% for infected Vero E6 cell line, Carvacrol, Thymoquinone caused inhibition to about 98%, Chloroquine as a positive control caused inhibition to 98% and Thymol show the lowest inhibition percentage 96% for infected Vero E6 cell line.

The results showed significantly difference between natural products effect with (P-value<0.0001) as shown in **Figure 5**. These results indicate that Hesperidine and other natural compounds as Carvacrol and Thymoquinone could be therapeutic agent against SARS-CoV-2 in Egypt as treatment resulted in the effective loss of essentially all viral material by time.




Figure 5 The antiviral effect of Hesperidin, Carvacrol, Thymoquinone, Chloroquine and Thymol against SARS-CoV-2 *in vitro*. The values are represented as means \pm SD (n=2) (*p<0.0001).

Eventually, development of an effective anti-viral for SARS-CoV-2, if given to patients early in infection, could help to limit the viral load, prevent severe disease progression and limit person-person transmission. Benchmarking testing of those natural compounds against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action would thus be important as soon as practicable.

Conclusion

These results indicate that Hesperidine and other natural compounds as Carvacrol and Thymoquinone could be therapeutic agent against SARS-CoV-2 in Egypt as treatment resulted in the effective loss of essentially all viral material by time.

Eventually, development of an effective anti-viral for SARS-CoV-2, if given to patients early in infection, could help to limit the viral load, prevent severe disease progression and limit person-person transmission. Benchmarking testing of those natural compounds against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action would thus be important as soon as practicable.

Ethics approval and consent to participate

Not applicable

Consent to publication

Not applicable

Availability of data and material

The docking structures are available upon request from the corresponding author.

Competing interests

All the authors declare that there is no competing interest in this work.

Funding

Not applicable

Authors' contributions

1-Mohamed Gomaa Seadawy, *In Vitro* work, Writing, Editing and Molecular Docking

2-Ahmed Fawzy, Gad Molecular docking

3-Mohamed Shamel Eldesoky, Data analysis

4-Bassem Elsayed Elharty, Molecular docking

5-Mostfa Fetooh Mohamed, *In vitro* study

6-Abdo Elfiky, Molecular docking

7-Aya Ahmed, Molecular docking and Editing

8-Abdel Rahman Nabwi Zekri, Reviewing

9-Sherine Helmy, Reviewing

Acknowledgement

Not applicable

References

1. Chan JFW, Yuan S, Kok KH (2020) A familial cluster of pneumonia

associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. *The Lancet* 395: 514-23.

2. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. *J American Med Asso* 323(13): 1239-42.
3. Wu J, Wu X, Zeng W (2020) Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. *Investigative Radiology* 55(5): 257-61.
4. Ultee A, Slump RA, Steging G, Smid EJ (2000) Antimicrobial activity of carvacrol toward *Bacillus cereus* on rice. *J of food protec* 63(5): 620-4.
5. Ultee A, Slump RA, Steging G, Smid EJ (2000) Antimicrobial activity of carvacrol toward *Bacillus cereus* on rice. *J of food prote* 63(5): 620-4.
6. Zanzwar AA, Badole SL, Shende PS, Hegde MV, Bodhankar SL (2014) Cardiovascular effects of hesperidin: A flavanone glycoside. *Polyphenols in human health and disease: Elsevier; 2014: 989-92.*
7. Jadeja RN, Devkar RV (2014) Polyphenols and flavonoids in controlling non-alcoholic steatohepatitis. *Polyphe in Hum Heal and Dise: Elsevier 2014: 615-23.*
8. Mollazadeh H, Hosseinzadeh H (2014) The protective effect of *Nigella sativa* against liver injury: A review. *Iranian j of basic medi scie* 17(12): 958-66.
9. Rahmani AH, Aly SM (2015) *Nigella sativa* and its active constituents thymoquinone shows pivotal role in the diseases prevention and treatment. *Asian J Pharm Clin Res* 8(1): 48-53.
10. Smith RD (1980) Avicenna and the canon of medicine: A millennial tribute. *Weste J of Medici* 133(4): 367.
11. Ahmad A, Husain A, Mujeeb M (2013) A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asia Paci j of tropi biomedic* 3(5): 337-52.
12. Ulasli M, Gurses SA, Bayraktar R (2014) The effects of *Nigella sativa* (Ns), *Anthemis hyalina* (Ah) and *Citrus sinensis* (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. *Mol Biol Rep* 41(3): 1703-11.
13. Salem AM, Bamasa AO, Qutub HO (2017) Effect of *Nigella sativa* supplementation on lung function and inflammatory mediators in partly controlled asthma: A randomized controlled trial. *Annals of Saudi medicine* 37(1): 64-71.
14. Boskabady MH, Javan H, Sajady M, Rakhshandeh H (2007) The possible prophylactic effect of *Nigella sativa* seed extract in asthmatic patients. *Funda and clinical pharma* 21(5): 559-66.
15. Mahboubi M (2018) Natural therapeutic approach of *nigella sativa* (Black Seed) fixed oil in management of sinusitis. *Integra mediciresea* 7(1): 27-32.

16. Elfiky AA, Ismail AM, Elshemey WM (2020) Recognition of gluconeogenic enzymes; Icl1, Fbp1, and Mdh2 by Gid4 ligase: A molecular docking study. *J of Molecu Recogni* 33(5): e2831.
17. Leach A (2001) *Molecular modelling: Principles and applications* (2nd Edition): Prentice Hall.
18. Elfiky AA (2020) Novel guanosine derivatives against Zika virus polymerase in silico. *J of Med Virolo* 92(1): 11-6.
19. Ganesan A, Barakat K (2017) Applications of computer-aided approaches in the development of Hepatitis C Antiviral Agents. *Exper Opini on Drug Discove* 12(4): 407-25.
20. Hasani HJ, Barakat KH (2016) Protein-Protein docking: Are we there yet? *Methods and algorithms for molecular docking-based drug design and discovery: IGI Global* 2016: 173-95.
21. Elfiky AA, Ismail A (2019) Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. *Life Sciences* 238: 116958.
22. 1.7.6 V. The PyMOL Molecular Graphics System, Version 1.7.6 Schrödinger, LLC.
23. Kim S, Thiessen PA, Bolton EE (2015) PubChem substance and compound databases. *Nucleic acids research* 44(D1): D1202-D13.
24. Berman H, Henrick K, Nakamura H (2003) Announcing the worldwide Protein Data Bank. *Nat Struct Biol* 10(12): 980.
25. Morris GM, Huey R, Lindstrom W (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* 30(16): 2785-91.
26. Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* 31(2): 455-61.
27. Elfiky AA (2020) Reply to a letter to the editor. *Life sciences* 252: 117715.
28. Abu-Melha S, Edrees MM, Riyadh SM, Abdelaziz MR, Elfiky AA, et.al (2010) Clean Grinding Technique: A facile synthesis and in silico antiviral activity of hydrazones, pyrazoles, and pyrazines bearing thiazole moiety against sars-cov-2 main protease (M(pro)). *Molecules* 25(19).
29. Elfiky AA, Ibrahim IM, Ismail AM, Elshemey WM. A possible role for GRP78 in cross vaccination against COVID-19. *J Infection*.
30. Alaa Ismail AE (2020) SARS-CoV-2 Spike behavior in situ: A Cryo-EM Images for a better understanding of the COVID-19 pandemic. *Signal transduction and targeted therapy* 2020; in press.
31. Elfiky A (2020) SARS-CoV-2 Spike-Heat Shock Protein A5 (GRP78) recognition may be related to the immersed human coronaviruses. *Front in Pharmaco; In press*.
32. Yan R, Zhang Y, Li Y, Xia L, Guo Y et al. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 367(6485): 1444-8.
33. Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020.
34. Mendonca P, Soliman KF (2020) Flavonoids activation of the transcription factor Nrf2 as a hypothesis approach for the prevention and modulation of SARS-CoV-2 Infection severity. *Antioxidants* 9(8): 659.
35. Mariappan VSRR, Balakrishna Pillai A. Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-COV-2. *IUBMB Life; n/a(n/a)*.
36. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunolo Metho* 65(1): 55-63.
37. Hayden FG, Cote KM, Douglas RG (1980) Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. *Antimicro agent and chemoth* 17(5): 865-70.
38. Adem s, Eyupoglu V, Sarfraz I (2020) Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19. *Phytomedicine: 153310*.
39. Elfiky AA (2020) Natural products may interfere with SARS-CoV-2 attachment to the host cell. *J of Biomol Structe and Dynam* 2020: 1-10.
40. Noor NA, Fahmy HM, Mohammed FF, Elsayed AA, Radwan NM (2015) *Nigella sativa* ameliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats. *Int J Clin Exp Pathol* 8(6): 6269-86.
41. Elfiky AA, Baghdady AM, Ali SA, Ahmed MI (2020) GRP78 targeting: Hitting two birds with a stone. *Life Sciences* 260: 118317.
42. Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sciences* 248: 117477.
43. Elfiky AA (2020) Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences* 253: 117592.
44. Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. *J Biomo Struct and Dynam* 2020: 1-9.
45. Jin Z, Du X, Xu Y (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature* 582(7811): 289-93.
46. Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA (2020) COVID-19 spike-host cell receptor GRP78 binding site prediction. *J Infection* 80(5): 554-62.
47. Korber B, Fischer WM, Gnanakaran S (2020) Tracking changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell* 182(4): 812-27.e19.
48. Ke Z, Oton J, Qu K (2020) Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature*.